ATP III


Also found in: Wikipedia.

ATP III

Adult Treatment Panel III. A brief overview of the National Cholesterol Education Program’s (NCEP) updated clinical guidelines for detecting, evaluating, and treating high cholesterol in adults.
Summary ATP III recommends that all adults above age 20 should get a fasting baseline lipoprotein profile every 5 years.
Rationale The profile is a parameter which, like diabetes, hypertension and other “traditional” heart disease risk factors, serves as a basis for determining the intensity of risk-reducing interventions.
Mentioned in ?
References in periodicals archive ?
In that context, imagine two men, both of whom have blood pressures and plasma TG concentrations high enough to satisfy the ATP III criteria to merit the diagnosis of the metabolic syndrome, but neither had a large enough waist or a high enough fasting plasma glucose to qualify for that diagnosis.
adults have LDL cholesterol levels in accordance with ATP III guidelines.
Lear seems to have overlooked the overall thrust of my comments concerning the relationship between obesity, insulin resistance, and the ATP III criteria for identifying the metabolic syndrome.
This population, identified using National Cholesterol Education Program (NCEP) ATP III guidelines, comprised men aged at least 45 years and women aged at least 55 years with moderately high LDL cholesterol (130 mg/dL to 170 mg/dL) and one additional CHD risk factor.
ATP III recommendations are solidly based on accumulating evidence concerning the contribution of lipoproteins and other risk factors in development of coronary heart disease (CHD) (3) and are more consistent with emerging international consensus (4, 5), for example, in increased emphasis on the risk associated with high triglycerides (TGs) (6).
Atherotech Diagnostics Lab's patented lipid profile fully complies with consensus statement, current NCEP ATP III guidelines
Using the ATP III criteria, analysis of data from the Third National Health and Nutrition Examination Survey (NHANES III) was performed to estimate the prevalence of metabolic syndrome in the United States.
It sounds like when the new ATP IV guidelines appear, there is a good chance they will call for more aggressive, generic statin--based risk reduction for primary prevention than current ATP III recommendations.
Diagnosis of MS was based on modified WHO criteria (microalbuminuria was excluded) (17), NCEP ATP III criteria (20), modified NCEPATP III criteria (18) and IDF criteria (17) (Table I).
Achievement of NCEP ATP III Treatment Goals African Americans 54% Non-Hispanic Whites 69% Note: Table made from bar graph.
Patients who didn't meet the NCEP ATP III goal levels for LDL cholesterol had a 13% elevated risk of a cardiovascular event, compared with patients who met lipid goals, the researchers noted.
ATP III recommends an LDL cholesterol of below 100 mg/dL as optimal, yet a better goal for transplant patients is below 60 mg/dL.